Bio-Rad Laboratories 

$296.86
116
-$0.23-0.08% Thursday 20:00
+$0.00+0%Thursday 20:00After hours

Statistics

Day High
292.27
Day Low
292.19
52W High
343.12
52W Low
236.73
Volume
544
Avg. Volume
-
Mkt Cap
7.94B
P/E Ratio
49.97
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
1.73
2.12
2.51
2.9
Expected EPS
1.747616
Actual EPS
N/A

Financials

29.42%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
5.17BRevenue
1.52BNet Income

Analyst Ratings

303.33Average Price Target
The highest estimate is 320.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BIO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Thermo Fisher Scientific
TMO
Mkt Cap190.65B
Thermo Fisher Scientific offers a broad range of products and services in the life sciences sector, directly competing with Bio-Rad's offerings in laboratory equipment and consumables.
Danaher
DHR
Mkt Cap138.86B
Danaher Corporation operates in similar segments as Bio-Rad, including life sciences and diagnostics, making them direct competitors in multiple product lines.
Illumina
ILMN
Mkt Cap26.71B
Illumina specializes in genomics and DNA sequencing technologies, competing with Bio-Rad's products in the genomics field.
Agilent Technologies
A
Mkt Cap38.41B
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Bio-Rad Laboratories
BIO.B
Mkt Cap8.84B
Bio-Rad Laboratories Class B shares represent a different class of stock of the same company but are listed separately, directly tied to the company's performance.
Waters
WAT
Mkt Cap36.76B
Waters Corporation provides analytical instruments for the life sciences sector, competing with Bio-Rad's chromatography and mass spectrometry products.
Bruker
BRKR
Mkt Cap9.27B
Bruker Corporation is a competitor in the life science analytical and diagnostic instruments sector, directly competing with several of Bio-Rad's product lines.
Qiagen NV
QGEN
Mkt Cap8.13B
QIAGEN is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, competing with Bio-Rad in the diagnostics and research sectors.
Baxter International
BAX
Mkt Cap11.38B
Baxter International operates in the medical devices and life sciences fields, competing with Bio-Rad in the broader healthcare and scientific research sectors.

About

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Show more...
CEO
Mr. Norman D. Schwartz
Employees
7700
Country
United States
ISIN
US0905722072

Listings

0 Comments

Share your thoughts

FAQ

What is Bio-Rad Laboratories stock price today?
The current price of BIO is $296.86 USD — it has decreased by -0.08% in the past 24 hours. Watch Bio-Rad Laboratories stock price performance more closely on the chart.
What is Bio-Rad Laboratories stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bio-Rad Laboratories stocks are traded under the ticker BIO.
Is Bio-Rad Laboratories stock price growing?
BIO stock has fallen by -1.31% compared to the previous week, the month change is a +0.86% rise, over the last year Bio-Rad Laboratories has showed a +18.01% increase.
What is Bio-Rad Laboratories market cap?
Today Bio-Rad Laboratories has the market capitalization of 7.94B
When is the next Bio-Rad Laboratories earnings date?
Bio-Rad Laboratories is going to release the next earnings report on July 30, 2026.
What were Bio-Rad Laboratories earnings last quarter?
BIO earnings for the last quarter are 1.89 USD per share, whereas the estimation was 1.97 USD resulting in a -4.21% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bio-Rad Laboratories revenue for the last year?
Bio-Rad Laboratories revenue for the last year amounts to 5.17B USD.
What is Bio-Rad Laboratories net income for the last year?
BIO net income for the last year is 1.52B USD.
How many employees does Bio-Rad Laboratories have?
As of July 05, 2026, the company has 7,700 employees.
In which sector is Bio-Rad Laboratories located?
Bio-Rad Laboratories operates in the Health & Wellness sector.
When did Bio-Rad Laboratories complete a stock split?
The last stock split for Bio-Rad Laboratories was on March 08, 2002 with a ratio of 2:1.
Where is Bio-Rad Laboratories headquartered?
Bio-Rad Laboratories is headquartered in Hercules, United States.